Who Owns Mounjaro?

• Parent Company: Eli Lilly and Company
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NYSE: LLY

• Founded: 2022
• Founders: Eli Lilly and Company

• Founded: 1876
• Headquarters: Indianapolis, Indiana, USA
• Company Type: Publicly Traded
• Stock: NYSE: LLY
• Revenue: approximately $45 billion (FY2024)
• Employees: Approximately 43,000

Visit Eli Lilly and Company website

• Headquarters: Indianapolis, Indiana, USA
• Manufacturing / Operations: United States, Europe

Mounjaro operates under Eli Lilly and Company's comprehensive sustainability framework, which addresses environmental responsibility, ethical pharmaceutical practices, and social impact across the healthcare and pharmaceutical industry. As a leading diabetes and obesity medication, Mounjaro's sustainability efforts focus on responsible manufacturing, patient safety, environmental compliance, and ethical business practices.

Environmental Sustainability in Pharmaceutical Manufacturing: Eli Lilly has implemented significant environmental initiatives across its manufacturing operations, including facilities that produce Mounjaro. The company purchased 58% of its purchased electricity from renewable sources in 2024, doubling its renewable energy purchasing compared to 2023. Eli Lilly's Environmental Standard establishes requirements to identify and manage environmental and energy-related aspects of operations, including energy efficiency improvements and waste reduction programs at manufacturing facilities producing tirzepatide.

Responsible Manufacturing and Supply Chain Ethics: Mounjaro is produced at Eli Lilly's specialized pharmaceutical facilities in the United States and Europe, where the company maintains comprehensive quality control systems and ethical manufacturing practices. Eli Lilly's Health and Safety Standard provides requirements for identifying and evaluating workplace hazards and establishing control measures to eliminate or reduce risks in pharmaceutical production environments. The company's manufacturing processes for Mounjaro follow Good Manufacturing Practices (GMP) and maintain high standards for environmental compliance.

Patient Safety and Ethical Clinical Development: Mounjaro's development followed comprehensive ethical guidelines for clinical research, including extensive safety monitoring and transparent reporting of results. The SURPASS clinical trial program enrolled over 40,000 patients across multiple studies, establishing robust evidence for both efficacy and safety. Eli Lilly maintains strict ethical standards for patient protection, informed consent, and data integrity in all clinical trials for Mounjaro and other pharmaceutical products.

Pharmaceutical Innovation and Access: Mounjaro represents significant pharmaceutical innovation through its dual GIP/GLP-1 receptor agonist mechanism, providing superior glycemic control and weight loss compared to existing treatments. Eli Lilly has implemented patient assistance programs to improve access to Mounjaro, recognizing the medication's high cost and the importance of ensuring availability for patients who need treatment for type 2 diabetes and obesity.

Environmental Compliance and Regulatory Standards: Eli Lilly maintains comprehensive environmental compliance across all operations, including manufacturing facilities that produce Mounjaro. The company's environmental programs focus on minimizing environmental impact through energy efficiency, waste reduction, and responsible resource management. Eli Lilly's sustainability strategy aligns with SASB standards for the Biotechnology and Pharmaceutical industry, addressing key environmental topics important to stakeholders.

Corporate Governance and Ethical Business Practices: Mounjaro operates under Eli Lilly's strong corporate governance framework, which includes ethical business practices, transparency in reporting, and accountability to stakeholders. The company's corporate governance structure ensures that pharmaceutical products like Mounjaro are developed and marketed with appropriate ethical consideration for patient safety, scientific integrity, and responsible commercial practices.

Community Engagement and Social Responsibility: Eli Lilly contributes to community health initiatives and diabetes education programs that support patients using Mounjaro and other diabetes treatments. The company's social responsibility programs include patient education, healthcare provider training, and support for diabetes research and advocacy organizations. These initiatives extend beyond Mounjaro specifically to address broader healthcare needs in communities where Eli Lilly operates.

Supply Chain Responsibility: Eli Lilly works with suppliers and partners who meet strict environmental and ethical standards for pharmaceutical manufacturing. The company's supply chain for Mounjaro includes raw material suppliers, manufacturing partners, and distribution channels that must comply with Eli Lilly's comprehensive supplier code of conduct, ensuring environmental responsibility and ethical business practices throughout the pharmaceutical supply chain.

Mounjaro has received significant recognition for pharmaceutical innovation, clinical excellence, and market impact since its launch in 2022, establishing itself as one of the most important pharmaceutical developments in recent years for diabetes and obesity treatment.

Pharmaceutical Innovation Recognition: Mounjaro's dual GIP/GLP-1 receptor agonist mechanism has been widely acknowledged as a breakthrough in diabetes treatment. The medication's superior efficacy compared to existing GLP-1-only agonists has been recognized by medical professionals and pharmaceutical industry organizations as representing a significant advancement in diabetes care. The SURPASS clinical trial program, particularly the SURPASS-2 head-to-head comparison showing tirzepatide's superiority over semaglutide, has been cited as exemplary clinical research methodology.

Market Leadership and Commercial Success: Mounjaro has achieved extraordinary commercial success, generating over $6 billion in global sales in 2024 and becoming one of the fastest-growing pharmaceutical products in history. This commercial performance has contributed to Eli Lilly being recognized as Company of the Year 2025 by pharmaceutical industry publications, with tirzepatide cited as the primary driver of the company's transformation and market leadership.

Clinical Excellence Recognition: The clinical trial results for Mounjaro have received recognition from medical societies and diabetes research organizations for demonstrating superior glycemic control and weight loss compared to existing treatments. The medication's ability to help patients lose 15-22% of their body weight in clinical trials has been acknowledged as a significant achievement in obesity management.

Regulatory Approval Achievement: Mounjaro's FDA approval in May 2022, followed by Zepbound's approval for obesity in November 2023, has been recognized as regulatory achievements that expanded treatment options for millions of patients. The dual approval strategy, mirroring Novo Nordisk's approach with semaglutide, has been cited as effective pharmaceutical commercial strategy.

Medical Community Recognition: Mounjaro has been widely adopted by healthcare providers and has received recognition from medical professional organizations for its clinical benefits and innovation in diabetes treatment. The medication's rapid adoption in clinical practice reflects its recognition by physicians as an important advancement in diabetes care.

Industry Leadership Recognition: Eli Lilly's success with Mounjaro has positioned the company as a leader in the rapidly growing GLP-1/GIP market, competing effectively against Novo Nordisk's semaglutide products. Industry analysts have recognized Eli Lilly's strategic execution in developing, launching, and scaling Mounjaro production to meet extraordinary demand.

Patient Advocacy Recognition: Mounjaro has been recognized by patient advocacy organizations and diabetes groups for providing effective treatment options for patients with type 2 diabetes. The medication's impact on patient quality of life and health outcomes has been acknowledged by healthcare organizations that support diabetes patients.

Mounjaro has faced several regulatory challenges and controversies since its launch, primarily related to promotional practices, safety concerns, and market access issues that have tested Eli Lilly's compliance and ethical marketing practices.

FDA Warning Letter for False and Misleading Claims (September 2025): The U.S. Food and Drug Administration issued a warning letter to Eli Lilly on September 9, 2025, regarding false and misleading claims in promotional materials for both Mounjaro and Zepbound. The FDA cited a direct-to-consumer video titled "An Oprah Special: Shame, Blame, and the Weight Loss Revolution" for making unsupported claims about the medications. The FDA specifically objected to statements suggesting that serious risks associated with Zepbound and Mounjaro had received "a lot of hype" or had been "overhyped," which the agency determined minimized the known risks of the medications.

Thyroid C-Cell Tumor Risk: Mounjaro carries a boxed warning about the potential risk of thyroid C-cell tumors, based on animal studies that showed dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors (adenomas and carcinomas) in rats. While it is unknown whether Mounjaro causes thyroid C-cell tumors in humans, this risk has been a significant safety concern that requires careful patient selection and monitoring.

Compounded Version Controversy: The FDA removed tirzepatide (both Mounjaro and Zepbound) from the drug shortage list in October 2024, which meant that compounded versions would no longer be allowed. This created controversy as patients who had been using compounded versions due to shortages or cost concerns had to transition to FDA-approved products, potentially affecting access and affordability.

High Cost and Access Issues: Mounjaro's list price of approximately $1,000 per month in the United States has generated significant controversy regarding medication affordability and access. Insurance coverage varies significantly by plan, leading to disparities in patient access to the medication. Eli Lilly has faced criticism for high pricing while also offering patient assistance programs to improve access.

Supply Chain and Manufacturing Challenges: The extraordinary demand for Mounjaro has led to periodic supply constraints and manufacturing challenges. Eli Lilly has invested billions of dollars in manufacturing capacity expansion to meet demand, but these supply issues have created frustration for patients and healthcare providers seeking consistent access to the medication.

Off-Label Use Controversy: Mounjaro's significant weight loss effects have led to widespread off-label use for obesity before Zepbound's approval, creating regulatory and ethical questions about promoting medications for uses not yet approved by the FDA. This off-label use has been both praised for helping patients and criticized for potentially bypassing appropriate regulatory oversight.

Competitive Market Dynamics: The intense competition between Eli Lilly (tirzepatide) and Novo Nordisk (semaglutide) has led to aggressive marketing and promotional practices that have drawn scrutiny from regulators and healthcare providers. Both companies have been criticized for minimizing risks and overemphasizing benefits in their marketing materials.

Side Effects and Safety Concerns: Mounjaro has been associated with gastrointestinal side effects including nausea, vomiting, diarrhea, and abdominal pain, which can be severe enough to cause treatment discontinuation. These side effects have been a source of controversy regarding the medication's risk-benefit profile and appropriate patient selection.

Regulatory Compliance Challenges: Beyond the 2025 FDA warning letter, Eli Lilly has faced ongoing scrutiny regarding its promotional practices and compliance with FDA regulations for pharmaceutical marketing. The company has had to balance commercial objectives with regulatory requirements in a highly competitive market environment.